Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

1,561

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Prophylaxis: Influenza
Interventions
BIOLOGICAL

TIVc_LOT A

Single IM (Intramuscular) administration dose of 0.5 mL of TIVc

BIOLOGICAL

TIVc_LOT B

Single IM administration dose of 0.5 mL of TIVc

BIOLOGICAL

TIVc_LOT C

Single IM administration dose of 0.5 mL of TIVc

BIOLOGICAL

TIVf

Single IM administration dose of 0.5 mL of TIVf

Trial Locations (24)

Unknown

Anaheim Clincial Trials, Anaheim

Northern California Clinical Research Center, Redding

Southern California CRC, San Diego

Broward Research Group, Hollywood

Comprehensive Clinical Trials, LLC, West Palm Beach

Palm Bech Research, West Palm Beach

Meridian Clinical Research, Savannah

Johnson County Clin-Trials, LLC, Lenexa

Heartland Research Associates, LLC, Wichita

Milford Emergency Associate,Inc, Milford

Meridian Clinical Research, Omaha

Rochester Clinical Research, Inc, Rochester

PMG Research of Charlotte, Charlotte

PMG Research of Hickory, Hickory

PMG Research of Raleigh, Raleigh

New Horizons Clinical Research, Cincinnati

Columbia Research Group, Inc, Portland

Omega Medical Research, Warwick

Clinical Research Solutions, LLC, Franklin

Clinical Research Associates, Inc, Nashville

Foothill Family Clinc South, J. Lewis Research Inc., Salt Lake City

Foothill Family Clinic, J. Lewis Research Inc., Salt Lake City

Jordan River Family Medicine, J. Lewis Research, Inc., South Jordan

Clinical Research Associates, Norfolk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY